• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for VUMERITY issued to BIOGEN INC

    9/16/24 6:24:32 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BIIB alert in real time by email
    New Drug Application (NDA): 211855
    Company: BIOGEN INC
    • Email

    Products on NDA 211855

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    VUMERITY DIROXIMEL FUMARATE 231MG CAPSULE, DELAYED RELEASE;ORAL Prescription None Yes Yes

    Approval Date(s) and History, Letters, Labels, Reviews for NDA 211855

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    10/29/2019 ORIG-1 Approval Type 2 - New Active Ingredient STANDARD Label (PDF)
    Letter (PDF)
    Review
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211855s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/211855Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211855Orig1s000TOC.cfm
    Supplements
    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
    09/11/2024 SUPPL-17 Label (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211855s017lbl.pdf
    12/13/2023 SUPPL-16 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211855s016lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/211855Orig1s016ltr.pdf
    03/22/2024 SUPPL-15 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211855s015lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/211855Orig1s015ltr.pdf
    11/16/2022 SUPPL-11 Manufacturing (CMC)-Packaging Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211855Orig1s011lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/211855Orig1s011ltr.pdf
    09/29/2022 SUPPL-10 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211855s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/211855Orig1s010ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/211855s010lbl.pdf
    02/10/2023 SUPPL-9 Efficacy-Labeling Change With Clinical Data Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211855s009lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/211855Orig1s009ltr.pdf
    02/10/2022 SUPPL-6 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211855s006lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/211855Orig1s006ltr.pdf
    01/29/2021 SUPPL-4 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211855s004lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/211855Orig1s004ltr.pdf
    08/21/2020 SUPPL-2 Labeling-Package Insert, Labeling-Patient Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211855s002lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/211855Orig1s002ltr.pdf

    Labels for NDA 211855

    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
    Patient Package Insert
    Note Url
    09/11/2024 SUPPL-17 Manufacturing (CMC) Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211855s017lbl.pdf
    03/22/2024 SUPPL-15 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211855s015lbl.pdf
    12/13/2023 SUPPL-16 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211855s016lbl.pdf
    02/10/2023 SUPPL-9 Efficacy-Labeling Change With Clinical Data Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211855s009lbl.pdf
    11/16/2022 SUPPL-11 Manufacturing (CMC)-Packaging Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211855Orig1s011lbl.pdf
    09/29/2022 SUPPL-10 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211855s010lbl.pdf
    02/10/2022 SUPPL-6 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211855s006lbl.pdf
    01/29/2021 SUPPL-4 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211855s004lbl.pdf
    08/21/2020 SUPPL-2 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211855s002lbl.pdf
    08/21/2020 SUPPL-2 Labeling-Patient Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211855s002lbl.pdf
    10/29/2019 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211855s000lbl.pdf
    Get the next $BIIB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIIB

    DatePrice TargetRatingAnalyst
    4/28/2025$118.00Buy → Hold
    HSBC Securities
    4/4/2025Buy → Hold
    Argus
    2/11/2025$160.00Mkt Perform
    Bernstein
    1/2/2025$315.00 → $138.00Overweight → Neutral
    Piper Sandler
    12/20/2024$230.00 → $164.00Outperform → Market Perform
    BMO Capital Markets
    12/16/2024$175.00Buy → Hold
    Stifel
    12/10/2024$178.00Neutral
    BofA Securities
    12/9/2024$250.00 → $180.00Buy → Hold
    Jefferies
    More analyst ratings

    $BIIB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Dorsa Caroline bought $151,559 worth of shares (1,235 units at $122.72), increasing direct ownership by 5% to 27,842 units (SEC Form 4)

      4 - BIOGEN INC. (0000875045) (Issuer)

      5/5/25 4:17:10 PM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rowinsky Eric K bought $101,256 worth of shares (455 units at $222.54), increasing direct ownership by 2% to 20,629 units (SEC Form 4)

      4 - BIOGEN INC. (0000875045) (Issuer)

      2/20/24 9:13:26 PM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BIIB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for VUMERITY issued to BIOGEN INC

      Submission status for BIOGEN INC's drug VUMERITY (ORIG-1) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/12/2024. Application Category: NDA, Application Number: 761347, Application Classification: Type 3 - New Dosage Form

      9/16/24 6:52:10 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for VUMERITY issued to BIOGEN INC

      Submission status for BIOGEN INC's drug VUMERITY (SUPPL-17) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/11/2024. Application Category: NDA, Application Number: 211855, Application Classification: Manufacturing (CMC)

      9/16/24 6:24:32 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for VUMERITY issued to BIOGEN INC

      Submission status for BIOGEN INC's drug VUMERITY (SUPPL-15) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211855, Application Classification: Labeling

      3/25/24 4:41:37 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BIIB
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Biogen Inc.

      DEFA14A - BIOGEN INC. (0000875045) (Filer)

      6/2/25 9:20:36 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Biogen Inc.

      144 - BIOGEN INC. (0000875045) (Subject)

      5/19/25 11:24:00 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Biogen Inc.

      8-K - BIOGEN INC. (0000875045) (Filer)

      5/12/25 4:45:12 PM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BIIB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

      Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old with Friedreich ataxia, a rare neurodegenerative disorderBRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA populationOmaveloxolone is currently marketed under the brand name SKYCLARYS® for the treatment of adults and adolescents aged 16 years and older affected by Friedreich ataxia CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) --  Biogen Inc. (NASDAQ:BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone

      6/18/25 7:30:27 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity

      Dapirolizumab pegol (DZP) showed efficacy across multiple clinical endpoints in the PHOENYCS GO study, including fatigue and measures of disease activityDZP showed consistent improvements in fatigue, a common and debilitating symptom of systemic lupus erythematosus (SLE)At Week 48, more individuals receiving DZP experienced no or low disease activity compared to standard of care with differences observed as early as Week 12 BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ:BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L

      6/12/25 1:00:39 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

      BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. "We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Dr. Radhakrishnan's deep and meaningful experience in global drug development will be invaluable as we quickly advance our novel Duchenne programs into multiple patient-focused clinical trials throughout this year," said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. "I'm honored to join the Board of Entrada

      6/3/25 7:00:00 AM ET
      $BIIB
      $TRDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $BIIB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Pangalos Menelas N

      4 - BIOGEN INC. (0000875045) (Issuer)

      6/18/25 5:05:17 PM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Minor Lloyd was granted 2,370 shares (SEC Form 4)

      4 - BIOGEN INC. (0000875045) (Issuer)

      6/18/25 4:54:06 PM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Patolawala Monish D was granted 2,370 shares, increasing direct ownership by 177% to 3,710 units (SEC Form 4)

      4 - BIOGEN INC. (0000875045) (Issuer)

      6/18/25 4:53:06 PM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care